Sebastian Zundler1, Deike Strobel2, Bernhard Manger3, Markus F Neurath2, Dane Wildner2. 1. Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany. sebastian.zundler@uk-erlangen.de. 2. Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany. 3. Department of Medicine 3, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Abstract
PURPOSE OF REVIEW: Polyarthritis can have numerous reasons and may thus constitute a challenge for differential diagnosis. One rare potential reason for sterile polyarthritis is underlying pancreatic disease with systemic hyperlipasemia, most often accompanied by painful skin lesions caused by a subcutaneous inflammatory process known as panniculitis. Systematic evidence on pancreatic panniculitis and polyarthritis is limited, particularly regarding its feature as facultative paraneoplasia with underlying intra- or even extra-pancreatic malignancy. Therefore, we will summarize the current knowledge about this orphan disease including epidemiological, pathophysiological, diagnostic, and treatment aspects in the present review. RECENT FINDINGS: Although direct evidence is lacking, it is highly probable that pancreatic polyarthritis and panniculitis are caused by peripheral lipolytic activity of lipase systemically circulating due to benign (e.g., acute or chronic pancreatitis) or malign (e.g., acinar cell carcinoma (ACC) or adenocarcinoma) pancreatic disease. In the latter case, pancreatic polyarthritis and panniculitis are associated with poor outcome. Pancreatic polyarthritis and panniculitis should always be included into diagnostic considerations, and once suspected, a thorough work-up to identify the underlying disease has to be performed.
PURPOSE OF REVIEW: Polyarthritis can have numerous reasons and may thus constitute a challenge for differential diagnosis. One rare potential reason for sterile polyarthritis is underlying pancreatic disease with systemic hyperlipasemia, most often accompanied by painful skin lesions caused by a subcutaneous inflammatory process known as panniculitis. Systematic evidence on pancreatic panniculitis and polyarthritis is limited, particularly regarding its feature as facultative paraneoplasia with underlying intra- or even extra-pancreatic malignancy. Therefore, we will summarize the current knowledge about this orphan disease including epidemiological, pathophysiological, diagnostic, and treatment aspects in the present review. RECENT FINDINGS: Although direct evidence is lacking, it is highly probable that pancreatic polyarthritis and panniculitis are caused by peripheral lipolytic activity of lipase systemically circulating due to benign (e.g., acute or chronic pancreatitis) or malign (e.g., acinar cell carcinoma (ACC) or adenocarcinoma) pancreatic disease. In the latter case, pancreatic polyarthritis and panniculitis are associated with poor outcome. Pancreatic polyarthritis and panniculitis should always be included into diagnostic considerations, and once suspected, a thorough work-up to identify the underlying disease has to be performed.
Authors: Rachel Pimenta Riechelmann; Paulo Marcelo Hoff; Renato Alonso Moron; Luiz Heraldo da Câmera Lopes; Antonio Carlos Buzaid Journal: Int J Gastrointest Cancer Date: 2003
Authors: Javier Narváez; Maria Marta Bianchi; Pilar Santo; Diana de la Fuente; Valeria Ríos-Rodriguez; Ferran Bolao; José Antonio Narváez; Joan Miquel Nolla Journal: Semin Arthritis Rheum Date: 2008-12-13 Impact factor: 5.532
Authors: Sebastian Zundler; Ramona Erber; Abbas Agaimy; Arndt Hartmann; Franklin Kiesewetter; Deike Strobel; Markus F Neurath; Dane Wildner Journal: BMC Cancer Date: 2016-02-20 Impact factor: 4.430
Authors: Lena Dreikhausen; Nadine Schulte; Sebastian Belle; Philip Weidner; Johannes Moersdorf; Christoph Reissfelder; Matthias P Ebert; Tianzuo Zhan Journal: Visc Med Date: 2021-03-29
Authors: Albrecht Betrains; Wouter Rosseels; Elke Van Mieghem; Steven Vanderschueren; Jochen Nijs Journal: Clin Rheumatol Date: 2020-08-10 Impact factor: 2.980